Gene Tx is a journalist who writes for Endpoints News, a leading source for biotech and pharmaceutical news. With a focus on the latest developments in the industry, Gene covers a wide range of topics including clinical trials, gene editing, IPOs, and regulatory updates. Gene's expertise lies in providing insightful and timely reporting on the ever-evolving world of biotechnology.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Gene Tx's coverage centers around gene therapy, biotech, and healthcare & pharmaceutical industry. The majority of the articles are comprised of press releases and private sector announcements, with a significant emphasis on FDA approvals and clinical trials.
If reaching out to Gene Tx, consider providing insights or access to exclusive data related to gene therapy companies, FDA regulatory affairs within the biotech space, IPOs in the healthcare sector or detailed analysis of clinical trial results in these areas. Additionally, sources with insider knowledge into private sector developments such as mergers/acquisitions would likely be valuable for this journalist's coverage.
Due to Gene Tx's focus on these specific topics within the broader realm of healthcare and pharmaceuticals, pitches should align closely with these themes while offering unique perspectives or newsworthy information relevant to ongoing trends in gene therapy and biotechnology industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Lei Lei Wu
Beam Therapeutics reported promising trial data from seven sickle cell patients treated with their gene-edited therapy, showing over 60% fetal hemoglobin expression and resolved anemia. The company joins bluebird bio and Vertex/CRISPR Therapeutics in developing sickle cell treatments. One patient died from chemotherapy-related complications.
By: Gene Tx
SAN DIEGO — Gilead and Arcellx say their experimental multiple myeloma cell therapy anito-cel could be a safer rival to field leaders Legend Biotech and Johnson …
By: Gene Tx, Andrew Dunn
What started as two CEOs eating tacos and talking biotech led to a merger and a new company. The epigenetic editing startup Chroma Medicine and …
By: Gene Tx
Editas Medicine will eliminate about 180 roles after failing to find a commercial partner for its experimental sickle cell therapy, and will halt development of …
Roche has officially discontinued a Phase 3 hemophilia A gene therapy from its Spark Therapeutics unit, a spokesperson for the Swiss pharma told Endpoints News …
By: Gene Tx
Bristol Myers Squibb is ending a pair of cell therapy collaborations with Immatics and nixing a separate agreement with Century Therapeutics for natural killer cell …
By: Gene Tx
Shinobi Therapeutics, an off-the-shelf cell therapy developer, told Endpoints News it has hired its first chief scientific and medical officers as it also nabs two …
By: Gene Tx
Ring Therapeutics, a startup looking to advance a new type of virus to deliver gene therapies, has let go “just under 50%” of its workforce …
By: Gene Tx
Sangamo has made another gene therapy deal to keep the lights on for a few more months, extending its funding by another three months until …
By: Nicole DeFeudis, Gene Tx
Mesoblast's stock surged on Thursday after the company won FDA approval for its twice-rejected graft-versus-host disease therapy.
(833) 317-6278 
